MeSH tree: C15.378.553.546
The U.S. Food and Drug Administration has approved Taiho Oncology's Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older ...
5 hours ago
0
1
For patients with breast cancer, administration of pegfilgrastim 72 hours postchemotherapy reduces pegfilgrastim-induced bone pain (PIBP) compared with administration at 24 and 48 hours, according to a study published online ...
Mar 24, 2026
0
2
For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine therapies leads to improved ...
Feb 2, 2026
0
6
For decades, patients undergoing blood cancer treatment have been told to avoid certain foods to reduce infection risk, guidance that some physicians hoped could safely be relaxed. Now, a University of Florida study offers ...
Dec 19, 2025
0
22
The U.S. Food and Drug Administration has approved Waskyra (etuvetidigene autotemcel) as the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS).
Dec 16, 2025
0
10
A study published in The Lancet showed a significant survival benefit for patients with oropharyngeal cancers who were treated with proton therapy (IMPT) compared to those treated with traditional radiation therapy (IMRT).
Dec 11, 2025
0
44
Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that needed urgent treatment or needing another treatment ...
Dec 9, 2025
0
9
Biliary tract cancers, including intrahepatic, perihilar, and extrahepatic cholangiocarcinoma and gallbladder cancer, are among the most aggressive gastrointestinal malignancies. Treatment options remain limited once the ...
Nov 28, 2025
0
13
Previously, results from the photon cohort of the NRG-BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not demonstrate improvement in overall survival (OS) ...
Oct 1, 2025
0
13
A team of doctors at Michigan Medicine have successfully treated a child in severe septic shock and multiorgan failure with their newly created therapeutic tool called the selective cytopheretic device.
Jun 26, 2025
0
22
